• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Applied DNA Sciences Inc.

    11/17/25 4:39:09 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email
    DEFA14A 1 tm2531488d2_defa14a.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.   )

     

    Filed by the registrant x

     

    Filed by a party other than the registrant o

     

    Check the appropriate box:

     

    Preliminary Proxy Statement o

     

    Confidential for Use of the Commission only (as permitted by Rule 14a-6(e)(2) o

     

    Definitive Proxy Statement o

     

    Definitive Additional Materials x

     

    Soliciting Material Pursuant to §§ 240.14a-12 o

         
    BNB Plus Corp.
    (Name of Registrant as Specified in Its Charter)
     
    N/A
    (Name of Person(s) Filing Proxy Statement if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required
       
    o Fee paid previously with preliminary materials
       
    o Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    BNB PLUS CORP.

     

    SUPPLEMENT TO THE DEFINITIVE PROXY STATEMENT
    FOR THE SPECIAL MEETING OF STOCKHOLDERS
    TO BE HELD ON DECEMBER 12, 2025

     

    November 17, 2025

     

    This proxy statement supplement (this “Supplement”) supplements the definitive proxy statement on Schedule 14A (the “Proxy Statement”) of BNB Plus Corp. (formerly known as Applied DNA Sciences, Inc.) (the “Company”), filed by the Company with the Securities and Exchange Commission on November 10, 2025 in connection with the Company’s Special Meeting of Stockholders scheduled to be held on December 12, 2025. This Supplement contains additional information relating to the change in the Company’s name since the filing of the Proxy Statement. Except as specifically supplemented by the information contained in this Supplement, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares.

     

    THE PROXY STATEMENT CONTAINS IMPORTANT INFORMATION AND THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT

     

    NAME CHANGE

     

    Effective November 13, 2025, the Company changed its name from “Applied DNA Sciences, Inc.” to “BNB Plus Corp.” (the “Name Change”), pursuant to an amendment to its amended and restated certificate of incorporation adopted by the Company’s Board of Directors and filed with the Secretary of State of the State of Delaware. Pursuant to the Delaware General Corporation Law, a stockholder vote was not necessary to effectuate the Name Change and it does not affect the rights of the Company’s stockholders.

     

    The Name Change was effectuated to reflect the Company’s commitment to delivering a yield-optimized, BNB-based digital asset treasury strategy leveraging the Binance ecosystem.

     

    The Proxy Statement contains important information and this Supplement should be read in conjunction with the Proxy Statement. Except as specifically supplemented by the information contained in this Supplement regarding the Name Change, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares. The Company does not intend to deliver updated proxy materials reflecting the Name Change. You should have received printed copies of the Proxy Statement and a Notice of Special Meeting by mail. If you have not already voted, you are urged to vote following the instructions contained in the Notice of Special Meeting mailed to stockholders entitled to notice of and to vote at the Special Meeting along with the Proxy Statement. If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote.

     

     

     

    Get the next $APDN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

    2/11/22 6:29:21 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

    8/13/21 6:30:16 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

    4/22/21 6:37:35 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ceccoli Joseph D. was granted 22,511 shares, increasing direct ownership by 2,251,100% to 22,512 units (SEC Form 4)

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    10/20/25 5:06:16 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Chief Financial Officer Jantzen Beth was granted 18,691 shares, increasing direct ownership by 623,033% to 18,694 units (SEC Form 4)

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    10/20/25 5:03:14 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Director Murrah Judith was granted 18,691 shares, increasing direct ownership by 623,033% to 18,694 units (SEC Form 4)

    4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

    10/20/25 5:00:49 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025 Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation

    Appoints TradFi and DeFi Leaders as Advisers, Including Anthony Scaramucci Enhanced Staking and Yield Strategy Focused on BNB Native Yield Integrating DeFi and Binance Ecosystem Expertise Offering Led by Institutional and Crypto-Native Investors including Galaxy, Off The Chain, Silvermine and Gaia Digital Assets Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production solutions, today announced up to $58 million in commitments for a private investment in public equity ("PIPE") offering led by institutional investors to initiate a digital asset treasury strategy based on BNB, the native cryptocurren

    9/29/25 3:08:00 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

    - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

    1/10/25 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Applied DNA Sciences Inc.

    DEFA14A - BNB PLUS CORP. (0000744452) (Filer)

    11/17/25 4:39:09 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BNB PLUS CORP. (0000744452) (Filer)

    11/17/25 4:36:27 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Applied DNA Sciences Inc.

    SCHEDULE 13G/A - BNB PLUS CORP. (0000744452) (Subject)

    11/14/25 8:14:14 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Financials

    Live finance-specific insights

    View All

    Applied DNA Sciences to Begin Trading Under New Ticker 'BNBX' Reflecting Digital Asset Treasury Strategy

    Ticker changing from ‘APDN' to ‘BNBX' effective October 7, 2025 Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company advancing a yield focused BNB digital asset treasury strategy and commercializing nucleic acid production solutions, today announced that it will change its ticker symbol on the Nasdaq Capital Market ("Nasdaq") from "APDN" to "BNBX", effective at the opening of trading on Tuesday October 7, 2025. The ticker BNBX underscores the Company's strategic commitment to a BNB-based treasury strategy designed to optimize yield generation and token accumulation within the Binance ecosystem. The Company plans to implement a differentiated

    10/6/25 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

    STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

    12/16/24 10:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

    STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

    8/7/24 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    View All

    Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

    Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

    9/6/23 9:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

    STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

    4/1/21 8:00:00 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/13/24 4:15:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

    11/7/24 10:11:34 AM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary